797 results about "Helicobacter pylori" patented technology

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

The invention relates to an automated decision support system, method, and apparatus for analysis and detection of bacteria in histological sections from tissue biopsies in general, and more specifically, of Helicobacter pylori (HP) in histological sections from gastric biopsies. The method includes image acquisition apparatus, data processing and support system conclusions, methods of transferring and storing the slide data, and pathologist diagnosis by reviewing and approving the images classified as containing bacteria, and more specifically HP findings.

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

The invention discloses a method for building a helicobacter pylori nucleic acid fingerprint spectrum, which comprises PCR (polymerase chain reaction) amplification, SAP (severe acute pancreatitis) enzymatic digestion, transcription and nuclease digestion, purification, mass spectrometer detection and the like. A helicobacter pylori nucleic acid fingerprint spectrum database is set up on the basis of the method. According to the generated mass peak spectrum of the experiment, the helicobacter pylori of a sample to be detected can be quickly identified, so the method can be widely applied in the fields of helicobacter pylori types and classification, environmental sanitation, public safety qunarantine and the like.

An anti-Helicobacter pylori agent comprising a compound represented by the formula:wherein A represents an aromatic ring group which may be substituted; R1 and R2, whether identical or not, each represent a hydrogen atom or a hydrocarbon group which may be substituted; R3 and R4, whether identical or not, each represent a hydrogen atom, a hydrocarbon group which may be substituted, an acyl group, a carbamoyl group which may be substituted, or a carboxyl group which may be esterified; or a salt thereof.

A process for producing an antibody enzyme which involves an antibody structure analysis step of confirming the presence of a catalyst triplet residue structure wherein a serine residue, an aspartate residue and a histidine residue or a glutamate residue are located stereostructurally close to each other in the stereostructure of an antibldy anticipated based on its amino acid sequence. Since the above-described catalyst triplet residue structure is a structure specific to an antibody enzyme, an antibody enzyme can be efficiently screened by using the same. Examples of the antibody enzyme as described above include an antibody enzyme against Helicobacter pylori urease and an antibody enzyme against chemokine receptor CCR-5.

The invention discloses a compound bismuth composition which contains antibiotics, a coated tablet of antibacterial agent and bismuth particle or powder, wherein the coated tablet is coated with Opadry II and the coating amount is 3 percent by weight; and the weight ratio of bismuth to the antibiotics to the antibacterial agent is 4-35:5-50:5-50. The invention also discloses a preparation method of the compound bismuth composition. The compound bismuth composition achieves good balance between the mutual action among active ingredients and the action of the active ingredients performed in stomach, and therefore is used for better eliminating the helicobacter pylori of stomach.

The invention relates to the field of functional foods, in particular to a composition and an application thereof in preparing a health-care product for alleviating stomach discomfort. According to the composition and the application thereof disclosed by the invention, fermented soybean flour, probiotics and prebiotics are in intercoordination effects, so that acute diseases of stomach pains and heartburn can be quickly alleviated, besides, the effects of helicobacter pylori can also be restrained, gastric mucosa is protected, and the purposes of adjusting gastroenteric functions and maintaining gastroenteric health are achieved. Experiments prove that 15 minutes after patients eat the composition provided by the invention, the symptoms of the stomach pains, the heartburn, water brash, nausea and cardialgia are alleviated, and the symptoms of 95% of patients are alleviated within 15 days.

Disclosed are a composition for detecting Helicobacter pylori including urea 0.5 to 4 percent by volume, potassium phosphate 0.05 to 0.2 percent by volume, phenate reagent solution 0.8 to 1.7 percent by volume, an indicator having a pKa of 6.5 to 8.5, 0.002 to 0.005 percent by volume, and a balance of water, a kit for detecting Helicobacter pylori using the composition and detecting method using the composition can determine quickly and accurately whether or not an infection by Helicobacter pylori exists, can obtain the same determination results after an elapse of time and can be used easily in an endoscope chamber.

The invention relates to compound probiotics and a preparation method thereof. The compound probiotics comprise ten or more probiotics and two or more prebiotics. The invention also provides the preparation method of the compound probiotics. The preparation method comprises the following steps: firstly, mixing the compound probiotics according to the proportion, passing through a sieve with 80 to 120 meshes, then taking siftage and weighing; secondly, mixing the weighed materials; thirdly, tabletting mixed materials. According to the compound probiotics and the preparation method thereof disclosed by the invention, by scientifically mixing the probiotics with the prebiotics, the efficacy of the compound probiotics is effectively improved, living cell concentration is high, and the efficacy realizing time of the probiotics is shortened; compared with other products in the market, the compound probiotics have the advantages that acid and bile salt resisting capabilities are good; if the compound probiotics are administrated for one month, the improvement rate of constipation reaches 100 percent, the improvement rate of chronic colitis reaches 100 percent, the positive-to-negative rate of helicobacter pylori reaches 82 percent, the rehabilitation rate of chemical liver injury reaches 88 percent, the rehabilitation rate of anaphylactic rhinitis is 91 percent, the rehabilitation rate of female vaginitis reaches 93 percent, the improvement rate of phlegm-dampness constitution reaches 100 percent, the improvement rate of damp-heat constitution reaches 100 percent, and the improvement rate of acnes reaches 98 percent.

The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

The invention discloses a method and a device for detecting and separating HP ELISA. According to the method, a prepared magnetic bead provided with HP, an enzyme-labeled antibody, an enzyme reaction substrate, a gastric juice sample and a cleaning fluid are placed in different liquid storage tanks on a micro-fluidic chip by the aid of an electric fluid force, and flow of liquids in the different liquid storage tanks is electrically controlled , so that ELISA is fully and automatically detected; and a detected fluorescence signal is taken as a trigger signal, so that an HP sample is fully and automatically separated. The device comprises a platform structure, the micro-fluidic chip and an electric cabinet, wherein the micro-fluidic chip comprises a glass sheet, a PDMS (polydimethylsiloxane) square plate and a driving electrode, a micro channel, a mixed channel and a detection area are formed in the surface of the PDMS square plate in a photoetching manner by the aid of a soft lithography technology, and the liquid storage tanks are arranged on the PDMS square plate. The device for detecting and separating the HP ELISA has the advantages as follows: the device is small in size, light in weight, convenient to carry and operate and low in construction cost and can be handheld for field detection, thereby facilitating popularization and application.

The invention belongs to the technical field of helicobacter pylori (Hp) examination and discloses a kit for fast culture, identification and a drug sensitivity test of Hp and an examination method therefor. The kit comprises a first culture tube, an identification reagent device and a drug sensitivity test unit. Through the first culture tube of Hp, bedside inoculation of a specimen is realized and the traditional sample transport and preservation processes are avoided; ordinary thermostat culture is realized and dependence on a CO2 incubator is eliminated; an Hp growth result is represented by a color change so that a result can be determined accurately by laypeople; through the combination of a growth promoting agent and a growth indicator, culture time is shortened and fast culture of Hp is realized; an Hp identification reagent, fast combination identification of Hp is realized; and through the drug sensitivity test unit of Hp, fast and accurate examination of drug sensitivity of Hp is realized. The kit and the examination method therefor can realize fast and accurate examination of Hp.

The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), E. coli O157:H7, fluoroquinolone-resistant Salmonella typhi, and the like. Furthermore, in the present methods, gallium compounds can be co-administered with one or more conventional antimicrobial agents to treat infectious diseases with reduced risks of creating multi-drug resistant pathogens. The methods of the present invention is also applicable to those microorganisms, such as ulcer-causing Helicobacter pylori, complete eradication of which so far has been difficult to achieve.

Disclosed is an oral administered compound colloid pectin bismuth preparation which comprises colloid pectine bismuth, antibiotics and antibacterial agent. The preparation process comprises dressing antibiotics and antibacterial agent micro-pellet core, mixing with colloid pectine bismuth and medically acceptable amount of excipient. After administration, the colloid pectine bismuth can form a membrane for the protection of gastric mucosa in stomach.

The strain of micro-organism Lactobacillus fermentum ME-3 is a novel anti-microbial and anti-oxidative probiotic. It has a high anti-microbial effect on Escherichia coli, Shigella sonnei, Staphylococcus aureus, Salmonella typhimurium, and moderate activity against Helicobacter pylori strains. The strain of micro-organism possesses Mn-superoxide dismutase and both its lysates and intact cells have high anti-oxidative activity, increasing the glutathione red-ox ratio in blood sera and able to capture toxic hydroxyl radicals. The strain of micro-organism could be used as a probiotic for the production of functional food (yoghurt, cheese) and non-comestibles (tablets, capsules) for the prophylaxis of intestinal and uroinfections, both for the prevention and treatment of chronic diseases, caused by prolonged oxidative stress.

The invention relates to a food-grade expression vector capable of realizing secretory expression of heterologous proteins in lactococcus lactis and a construction method and application thereof. The vector contains a nucleotide sequence as shown in SEQ ID (sequence identity) NO. 1. The construction method comprises the following steps of: amplifying signal peptide genes SPusp45 of lactococcus lactis Usp45 proteins through a PCR (polymerase chain reaction) method, connecting with a food-grade expression vector pNZ8149, using a connection product to transform Escherichia coli, screening and identifying positive transformation bacteria, and extracting recombinant plasmids to obtain a lactococcus lactis secretory expression vector pNZ8149-SPusp45. The invention further discloses the application of the pNZ8149-SPusp45 as a heterologous protein expression vector, including recombinant lactococcus lactis which is constructed by taking the pNZ8149-SPusp45 as the vector and has the secretory expression of helicobacter pylori UreB proteins and the application thereof.

The invention relates to a recombinant fusion protein vaccine and an attenuated live vector vaccine for treating and preventing helicobacter pylori (Hp) infection, and belongs to the field of biopharmaceutics. The recombinant fusion protein vaccine and the attenuated live vector vaccine for expressing the recombinant fusion protein are characterized in that: the recombinant fusion protein is formed by connecting immune protective function fragments of helicobacter pylori cytotoxin relevant gene protein CagA from helicobacter pylori, vacuolization cytotoxin VacA and urease subunit UreB linearly, and the immunogenicity and immune protection of the recombinant fusion protein are verified through animal experiments. The live vaccine has the advantages that: 1, an Hp fusion protein gene can beexpressed stably; 2, mucosa and systemic immune response can be induced after immunity; and 3, the method is convenient, the cost is low, and the economic benefit is obvious. Therefore, the attenuated live vector vaccine can be used as candidate vaccines for treating and preventing the Hp infection.

The invention discloses a recombinant helicobacter pylori protein vaccine and a preparation method thereof. The active ingredient recombinant fusion protein of the vaccine consists of recombinant LTAl-Ureal protein and LTB protein, the amino acid sequence of the recombinant LTAl-Ureal protein is shown as Seq ID No.1, the amino acid sequence of the LTB protein is shown as Seq ID No.2. Epitope-containing gene segments of Hp urease A subunit is inserted in an LTA subunit-encoded gene, a toxic part-containing segment is replaced to prepare a recombinant plasmid so as to express and obtain recombinant fusion protein polymer as a vaccine antigen, the fusion antigen and LTB protein pentamer are combined to form a hexamer structure, so that not only can the structure basis and activity of an LT mucosa adjuvant be remained, but also the toxicity can be removed, the immune response of organism muscosa can be effectively induced through immunity of mucosa path, to generate specific IgA antibody. The recombinant helicobacter pylori protein vaccine provides a vaccine manner for preventing and treating infection of helicobacter pylori.

The invention relates to a composition for the treatment and / or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and / or a disease associated with infection by said gastrointestinal pathogen in mammals.

The invention relates to a gene detection kit, in particular to a helicobacter pylori (HP) type and drug-resistant mutation gene detection kit. The kit comprises PCR (polymerase chain reaction) solutions and nucleic acid membrane strips for HP type and drug-resistant mutation gene detection; the PCR solutions comprise a PCR solution I, a PCR solution II, a PCR solution III and a PCR solution IV; the PCR solutions also contain a pair of internal control primers respectively. The HP type and drug-resistant mutation gene detection kit can be used for distinguishing two types of HP in one test, and can be used for detecting 15 mutation types of 9 hot spot mutational loci related with drug fastness of 5 therapeutics, a VacA gene and a CagA gene are used for typing, and a reference basis is provided for judgment of illnesses. Mutation types of drug-resistant mutation detection are more and more comprehensive, and the condition of genotypic resistance of HP from which a patient suffers is quickly and comprehensively evaluated.

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic / antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion. The present invention also relates to the use of one or more water soluble zinc salts, administered in combination with a therapeutic compound or agent (second therapeutic agent) which may be delivered orally with enhanced bioavailability (compared to compounds which are administered in the absence of water soluble zinc salts) or other favorable benefits. In addition, therapeutic agents which exhibit sensitivity to low pH may be advantageously orally administered in combination with an effective amount of at least one water soluble zinc salt. Compositions according to the present invention exhibit greater bioavailability of the active agent when formulated in combination with a water soluble zinc salt in oral dosage form than when administered with the water soluble zinc salt.

The invention discloses a probiotic bacteria powder composition and a product thereof, wherein, the probiotic bacteria powder composition is made by a method that a probiotic bacteria which has the functions of intestinal canal adsorption and PBMC (peripheral blood corpuscle cells of human being) analysis and can reduce allergy is combined with the same or another probiotic bacteria which can inhibit helicobacter pylori, and then the mycelium is embedded by making use of a wall material prescription, and finally frozen and dried to form the probiotic bacteria powder composition, while the probiotic bacteria product is prepared in a way that at least one kind of probiotic bacteria is homogeneously emulsified with grease and an antioxidant, emulsified with a dissolved membrane, and then filled into a dosage form of soft capsule; and the probiotic bacteria powder composition has the advantages of easy acquirability of raw materials and simple process, in addition, the probiotic bacteria product has the advantages of stable quality and easy conservation, so that the active bacteria can be fully retained and quickly restored to the stable state in the stomach acid environment; the method thereof can also protect the mycelium from being damaged by stomach acid and bile salt, and can be fully used in preparing similar formulations.

The present invention relates to flavanoid compounds of general formula (X1) wherein: R1 is selected from a group consisting of morpholinyl, N-methyl piperizinyl, piperidinyl and N,N′-dimethylamino groups, and n ranges from 3 to 6, and process for preparation thereof. The present invention relates to the demonstration of anti Helicobacter pylori activity and gastric antisecretory activity of semisynthetically designed flavonoid compounds, to be used for the prevention and treatment of gastroduodenal disorders in general and peptic ulcer diseases in particular. The present invention also relates to a hetero-dimeric bi-functional molecule that can be used as monotherapy substituting / replacing / overcoming currently used triple / quadruple therapy, thereby implicating / anticipating / envisaging its commercial applicability.

The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.